Synthaverse S.A.
Warsaw Stock Exchange SVE.WA
Synthaverse S.A. Price to Earnings Ratio (P/E) on January 14, 2025: 61.34
-
Synthaverse S.A. 52-week high Price to Earnings Ratio (P/E) is 84.60 on July 12, 2024, which is 37.91% above the current Price to Earnings Ratio (P/E).
-
Synthaverse S.A. 52-week low Price to Earnings Ratio (P/E) is 52.82 on March 06, 2024, which is -13.89% below the current Price to Earnings Ratio (P/E).
-
Synthaverse S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is 66.32.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. Mieczyslaw Starkowicz |
| IPO Date | July 29, 2011 |
| Location | Poland |
| Headquarters | Ul. Uniwersytecka 10 |
| Employees | 239 |
| Sector | Health Care |
| Industries | |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email